GUBRA A/S [CBOE] overview

HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) Following Gubra's Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ahead. As recommended by the Nomination Committee, the following members were re-elected to the Board: Jacob Jelsing Monika Lessl Alexander Thomas Martensen-Larsen Astrid Haug Arndt Justus Georg Schottelius Henriette Dræbye Rosenquist did not...

HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA) On Thursday, 3 April 2025 at 10:00 am (CEST), the annual general meeting of Gubra A/S (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm, with the following agenda: 1. The board of directors' report on the Company's activities during the past financial year 2. Presentation of the audited annual report for adoption 3. Resolution on the appropriation of profit or payment of loss...

HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA): With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, all closing conditions of the license agreement have today been satisfied and the license agreement has become effective. Contacts at Gubra: Media: Sofia Pitt Boserup,...

HØRSHOLM, DK / ACCESS Newswire / April 1, 2025 / Gubra (CPH:GUBRA) GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses of 1 mg and 2 mg GUBamy administered once-weekly for six weeks led to a dose dependent mean weight loss. LS Mean weight loss in the 2 mg cohort was -7.77% on day 43. In the placebo group there was an LS Mean weight gain of +1.99% on day 43. The body weight loss was sustained in a manner consistent...

HØRSHOLM, DK / ACCESS Newswire / March 28, 2025 / Gubra (CPH:GUBRA) With reference to AbbVie's (NYSE:ABBV) and Gubra A/S' (CPSE:GUBRA) joint announcement of March 3, 2025 regarding a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity, the US Federal Trade Commission today granted early termination of the waiting period under the HSR Act. Closing of the license agreement remains subject to other customary closing conditions....

HØRSHOLM, DK / ACCESS Newswire / March 10, 2025 / Gubra (CPH:GUBRA) Notice to convene ANNUAL GENERAL MEETING 2025 GUBRA A/S CVR NO. 30 51 40 41 To the shareholders of Gubra A/S (CVR no. 30 51 40 41), notice is hereby given of the annual general meeting of Gubra A/S (the " Company ") to be held on: THURSDAY, 3 APRIL 2025 AT 10:00 AM (CEST) GUBRA A/S HØRSHOLM KONGEVEJ 11B DK-2970 HØRSHOLM In accordance with article 12.1 of the articles of association the agenda of the meeting is as follows: 1....

HØRSHOLM, DK / ACCESS Newswire / March 03, 2025 / Gubra (CPH:GUBRA) Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure for developing and commercializing therapies for patients in need AbbVie (NYSE : ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug discovery within metabolic...